SCHEMBL20697372

SCHEMBL20697372

CO[C@H]1C[C@H](Oc2ncc(Cl)cc2[N+](=O)[O-])C1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 2/20 0.40
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
PIN1 Q13526 4/20 0.35
CHUK O15111 1/20 0.34
POLB P06746 2/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
LMNA P02545 1/20 0.33
AHR P35869 1/20 0.32
HSD11B1 P28845 1/20 0.32
IP6K1 Q92551 1/20 0.32
PKM P14618 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20697399 1.00 TYK2 (0.40) TYK2FFAR1FFAR4PIN1CHUK
SCHEMBL20697374 0.82 CNR1 (0.37) TYK2PIN1CHUKMAPK1AHR
SCHEMBL19171721 0.80 BCL6 (0.40) TYK2CHUKMAPTMAPK1
SCHEMBL8514116 0.79 PIN1 (0.44) PIN1CHUKPOLBMAPTMAPK1
SCHEMBL19171907 0.79 NOS3 (0.43) MAPK1LMNA
SCHEMBL20697468 0.77 TYK2 (0.42) TYK2CHUK
SCHEMBL20697467 0.77 TYK2 (0.42) TYK2CHUK
SCHEMBL20697419 0.77 ALDH1A1 (0.54) POLBMAPTMAPK1LMNANPC1
SCHEMBL20697327 0.77 ALDH1A1 (0.54) POLBMAPTMAPK1LMNANPC1
SCHEMBL20689130 0.76 TYK2 (0.45) TYK2FFAR4CHUKMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885FFAR1 4510/4885FFAR4 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.